The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
67
Modified release (MR) oral tablet
Matching oral tablet
Imbria Investigational Site
La Jolla, California, United States
Imbria Investigational Site
Los Angeles, California, United States
Imbria Investigational Site
San Francisco, California, United States
Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs
Time frame: Baseline through Week 14 Safety Follow-up
Change from baseline of peak oxygen consumption (VO2) and Oxygen uptake efficiency slope (OUES), measured by standardized cardiopulmonary exercise testing (CPET)
Time frame: Baseline, Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Imbria Investigational Site
Chicago, Illinois, United States
Imbria Investigational Site
Boston, Massachusetts, United States
Imbria Investigational Site
Burlington, Massachusetts, United States
Imbria Investigational Site
St Louis, Missouri, United States
Imbria Investigational Site
Morristown, New Jersey, United States
Imbria Investigational Site
New York, New York, United States
Imbria Investigational Site
Charlotte, North Carolina, United States
...and 4 more locations